IQVIA Holdings Inc. (NYSE: IQVIA) is a global provider of clinical research services, healthcare data, and advanced analytics used by pharmaceutical and biotechnology companies worldwide. Shares recently traded around $225 per share, giving the company a market capitalization of roughly $38.4 billion.
IQVIA operates at the center of outsourced drug development and data driven decision making. Looking at who owns IQVIA and recent insider trades helps show how large investors and company leadership may be approaching the stock today.
Who Are IQVIA’s Top Shareholders?
IQVIA’s shareholder base is led by major institutional investors. These firms tend to hold through market cycles, which can help support long term ownership stability, even as active managers adjust positions based on valuation and outlook.
- The Vanguard Group: 19,410,649 shares (11.40%), ~$4.38B value. Cut 186,587 shares (0.95%).
- Harris Associates L.P.: 11,387,265 shares (6.69%), ~$2.57B value. Cut 365,917 shares (3.11%).
- BlackRock Institutional Trust Company: 9,442,253 shares (5.54%), ~$2.13B value. Added 67,416 shares (0.72%).
- State Street Investment Management: 7,548,921 shares (4.43%), ~$1.70B value. Cut 75,923 shares (1.00%).
- GIC Private Limited: 6,541,387 shares (3.84%), ~$1.47B value. Cut 2,589,109 shares (28.36%).
- Geode Capital Management: 4,350,518 shares (2.55%), ~$980.7M value. Added 132,364 shares (3.14%).
- CPP Investments: 4,115,564 shares (2.42%), ~$927.7M value. Cut 52,915 shares (1.27%).
- AllianceBernstein L.P.: 3,597,572 shares (2.11%), ~$810.9M value. Added 41,643 shares (1.17%).
- Boston Partners: 3,556,708 shares (2.09%), ~$801.7M value. Added 1,581,766 shares (80.09%).
- Artisan Partners Limited Partnership: 3,433,957 shares (2.02%), ~$774.0M value. Added 161,085 shares (4.92%).
- Fidelity Management & Research Company: 3,316,997 shares (1.95%), ~$747.7M value. Added 653,006 shares (24.51%).
For investors, the mix of trimming and meaningful additions suggests IQVIA remains widely held but actively evaluated, with institutions expressing different views on valuation and near term expectations.
Hedge Fund Highlights
One notable move comes from Citadel Advisors, led by Ken Griffin, which increased its IQVIA position by over 1,100%, lifting its holdings to roughly $15M value. While the position remains small relative to Citadel’s overall portfolio, the sharp increase suggests rising interest at recent price levels.
Adage Capital Partners, founded by Robert Atchinson and Phillip Gross, also boosted its stake by nearly 280%, bringing its IQVIA position to approximately $26M value. The increase may indicate growing confidence in IQVIA’s role within healthcare data and clinical research infrastructure.
Glenview Capital Management, led by Larry Robbins, raised its IQVIA holdings by about 75%, taking its position to roughly $33M value. The move suggests Glenview may be building exposure gradually rather than making a single large entry.
Millennium Management, founded by Israel Englander, increased its position by just over 28%, with holdings now near $68M value. Given Millennium’s multi strategy approach, the increase may reflect a tactical allocation rather than a high conviction long term bet.
For investors, hedge fund activity appears constructive overall, with multiple funds adding exposure, though position sizes suggest measured interest rather than aggressive concentration.
Track the top shareholders of over 50,000 global stocks (It’s free) >>>
IQVIA’s Recent Insider Trades
Insider trades can offer useful context around how executives and directors may be managing personal exposure, though intent is not always clear.
- Ari Bousbib (Officer, Director): Sold shares across multiple transactions, ranging from roughly 800 to over 36,000 shares at prices between about $217 and $223; also recorded 50,000 and 77,592 shares at $59.90.
- John G. Danhakl (Director): Bought 158 shares at roughly $225.
- Colleen A. Goggins (Director): Bought 181 shares at roughly $225.
- James A. Fasano (Director): Bought 193 shares at roughly $225.
- Morris Leslie Wims (Director): Bought 146 shares at roughly $225.
For investors, insider activity appears measured and modest relative to IQVIA’s overall share count, with filings that look like a mix of small purchases and equity related transactions rather than a strong directional signal.
See recent insider trade data for over 50,000 global stocks (It’s free) >>>
What the Ownership & Insider Trade Data Tell Us
IQVIA’s ownership base remains anchored by large institutions such as Vanguard, BlackRock, and State Street, providing stability. At the same time, recent filings show meaningful differences in positioning among active managers and hedge funds, with several adding exposure at current price levels.
Insider activity appears cautious and mixed, with several sales and small director purchases that do not materially change ownership levels. For investors, the combined data suggest IQVIA continues to be viewed as a high quality healthcare services and analytics business, though opinions vary on valuation and near term upside, pointing to ongoing debate rather than clear consensus.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
